The efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: A multicenter study by the Turkish Oncology Group (TOG).

• DOI: 10.1200/jco.2024.42.16_suppl.e17534
• Publication Date: 2024-07-08T15:45:09Z
• Authors: Arif Akyildiz; Melis Gultekin; Ecem Yigit; Ecem Demir; Rashad Ismayilov; Melin Aydan Ahmed; Mustafa Buyukkor; Hasan Çağrı Yıldırım; Nilgun Yildirim; Efnan Algin; Seval Orman; Rumeysa Çolak; Esra Özen Engin; Havva Beyaz; Kamuran Ibis; Şefika Arzu Ergen; Sezin Yuce Sari; Yilmaz Tezcan; Ferah Yildiz; Zafer Arik
• Keywords: Chemoradiotherapy

e17534 Background: This multicentric study aimed to investigate the impact of cumulative cisplatin dose on clinical outcomes in locally advanced cervical cancer patients undergoing definitive chemoradiotherapy (CRT). Methods: A retrospective analysis was conducted 654 with stage IB3-IVA disease treated CRT. Radiotherapy (RT) applied as external beam pelvic or without para-aortic RT and brachytherapy. Concomitant chemotherapy form weekly 3-weekly cisplatin. Data demographics, treatment protocols, dose, adverse effects, survival were collected. Statistical analyses, including univariate multivariate Cox regression models, employed assess factors influencing progression-free (PFS) overall (OS). Results: The median 210 mg (range, 40-320 mg), it ≥200 503 (76.9%) patients. Median follow-up 35 months. 5-year PFS OS rates 66.9% 77.1%, respectively. Multivariate (MVA) identified poor performance status, non-squamous cell histology, presence lymph node metastasis hemoglobin <10 g/dl before CRT prognostic for both whole group. When III cases evaluated separately, below 200 also found be a significant factor (HR 1.79, 95% CI, 1.1 3.0, p=0.031). Conclusions: revealed that exceeding mg, particularly metastasis, significantly improved OS. Factors such anemia, toxicity-related challenges, comorbidities critical considerations planning. These findings emphasize delicate balance between maximizing therapeutic efficacy managing toxicity, guiding personalized approaches cancer. [Table: see text]